NGF and osteoarthritis: Nexvet successfully converted the rat anti-NGF mAb (αD11) into caninized and felinized anti-NGF mAbs, aimed at treating painful conditions, including osteoarthritis (OA), in dogs and cats (see Section 5.2) [20].